section name header

Indications

REMS


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: tachycardia, hypotension, palpitations

Derm: alopecia, ERYTHEMA MULTIFORME, oligohydrosis ( sweating), STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS

EENT: acute myopia, blurred vision, eye pain, secondary angle closure glaucoma, visual field defects

Endo: hypoglycemia

F and E: hypokalemia, metabolic acidosis

GI: altered taste, constipation, dry mouth, HEPATOTOXICITY

GU: serum creatinine, kidney stones

Metab: growth (children)

Neuro: headache, insomnia, paresthesia, cognitive impairment, dizziness, mood disorders, SEIZURES (FOLLOWING ABRUPT DISCONTINUATION), SUICIDAL IDEATION

Misc: ALLERGIC REACTION, hyperthermia

Interactions

Drug-drug:

Availability

(Generic available)

Route/Dosage

Renal Impairment

Hepatic Impairment

US Brand Names

Qsymia

Action

  • Phentermine: appetite and food consumption;
  • Topiramate: appetite and enhances satiety.
Therapeutic effects:
  • Weight loss.

Classifications

Therapeutic Classification: weight control agents

Pharmacologic Classification: appetite suppressants

Pharmacokinetics

Phentermine

Absorption: Extent of absorption following oral administration unknown.

Distribution: Unknown.

Metabolism/Excretion: Metabolized by the liver.

Half-Life: 19–24 hr.

Topiramate

Absorption: 80% absorbed following oral administration.

Distribution: Unknown

Metabolism/Excretion: Not extensively metabolized. 70% excreted unchanged in urine.

Half-Life: 21 hr.

Contr. Subst. Schedule

Schedule IV (C-IV)

Time/Action Profile

(weight loss)

ROUTEONSETPEAKDURATION
POwithin 8 wk16–32 wkunknown



Patient/Family Teaching

Pronunciation

FEN-ter-meen/toe-PYRE-a-mate